Journal Mobile Options
Table of Contents
Vol. 48, No. 1, 2002
Issue release date: March 2002
Chemotherapy 2002;48:42–48
(DOI:10.1159/000048587)

Protection Effects of Taurine Supplementation against Cisplatin-Induced Nephrotoxicity in Rats

Saad S.Y. · Al-Rikabi A.C.
aDepartment of Clinical Pharmacy, College of Pharmacy and bDepartment of Pathology, College of Medicine, King Saud University, Riyadh, Saudi Arabia

Individual Users: Register with Karger Login Information

Please create your User ID & Password





Contact Information











I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Abstract

Backgound: Taurine, which is the major intracellular free β-amino acid, is known to be an antioxidant and a membrane-stabilizing agent. This study was designed to investigate the protective role of taurine supplementation against cisplatin-induced nephrotoxicity. Methods: Male Wistar rats were divided into six groups and treated as follows: (1) saline-treated control drinking tap water, (2) saline-treated plus taurine-supplemented (1.5% taurine in the drinking water), (3) saline-treated plus taurine-depleted (3% β-alanine in the drinking water), (4) cisplatin-treated, CDDP 6 mg/kg intraperitoneally, (5) taurine-supplemented plus CDDP-treated and (6) taurine-depleted plus CDDP-treated. Rats were sacrificed 7 days after CDDP treatment, and serum as well as kidneys were isolated and analyzed. Results: CDDP-treated rats showed increased kidney weight as a percentage of total body weight, serum creatinine and BUN levels and decreased serum albumin and calcium levels. Also, CDDP treatment resulted in a depletion of kidney GSH content, a reduction in the kidney glutathione peroxidase (GSH-Px) activity and increased kidney MDA production level. Taurine supplementation attenuated CDDP-induced nephrotoxicity which was manifested by jeopardizing the elevation in serum creatinine and BUN levels and the reduction in serum albumin and calcium levels. Moreover, taurine supplementation restored kidney GSH content and GSH-Px activity and reduced platinum accumulation and MDA production levels in the kidney tissue following CDDP treatment. Histopathological examination of the kidney of CDDP-treated rats revealed tubular atrophy, tubular necrosis and desquamation of renal tubular cells. However, taurine supplementation protected against CDDP-induced histopathological changes. Conclusions: The data suggest that taurine supplementation effectively attenuates the accumulation of platinum within kidney tissue and counteracts the deleterious effect of CDDP on the renal tubular function.



Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. Links M, Lewis C: Chemoprotectants: A review of their clinical pharmacology and therapeutic efficacy. Drugs 1999;57/3:293–308.
  2. Maheswari KU, Ramachandran T, Rajaji D: Interaction of cisplatin with planar model membranes – Dose dependent change in electrical characteristics. Biochim Biophys Acta 2000;1463/2:230–240.
  3. Doyban DC, Levi J, Jacobs C, Kosek J, Weiner MW: Mechanisms of cisplatin-induced nephrotoxicity. II. Morphologic observations. J Pharmacol Exp Ther 1980;213:551–556.
  4. Gonzalez-Vitale JC, Hayes DM, Cvitkovic E, Sternberg SS: The renal pathology in clinical trials of cis-platinum-diaminedichloride. Cancer 1977;39:1362–1371.

    External Resources

  5. Miura K, Goldstein RS, Pasino DA, Hook JB: Cisplatin nephrotoxicity: Role of filtration and tubular transport of cisplatin in isolated perfused kidneys. Toxicology 1987;44:147–158.
  6. Gordon JA, Gattone VH: Mitochondrial alterations in cisplatin-induced acute renal failure. Am J Physiol 1986;250:F991–F998.

    External Resources

  7. Kim YK, Byun HS, Kim YH, Woo JS, Lee SH: Effect of cisplatin on renal function in rabbits: Mechanism of reduced glucose reabsorption. Toxicol Appl Pharmacol 1995;130:19–26.
  8. Zhang JG, Lindup WE: Cisplatin nephrotoxicity: Decreases in mitochondrial protein sulphydryl concentration and calcium uptake by mitochondria from rat renal cortical slices. Biochem Pharmacol 1994;47:1127–1135.
  9. Zhang JG, Lindup WE: Role of mitochondria in cisplatin-induced oxidative damage exhibited by rat renal cortical slices. Biochem Pharmacol 1993;45:2215–2222.
  10. Moore GA, Weis M, Orrenius S, O’Brien PJ: Role of sulfhydryl groups in benzoquinone-induced Ca2+ release by rat liver mitochondria. Arch Biochem Biophys 1988;267:539–550.
  11. Nicotera P, Bellom G, Orrenius S: Calcium-mediated mechanism in chemically induced cell death. Annu Rev Pharmacol Toxicol 1992;32:449–470.
  12. Richter C, Gogvadze V, Laffranchi R, Schlapbach R, Schweizer M, Suter M, Walter P, Yaffee M: Oxidants in mitochondria: From physiology to disease. Biochim Biophys Acta 1995;1271:67–74.
  13. Erdem A, Gundogan NU, Usubutun A, Kilinc K, Erdem SR, Kara A, Bozkurt A: The protective effect of taurine against gentamycin-induced acute tubular necrosis in rats. Nephrol Dial Transplant 2000;15:1175–1182.

    External Resources

  14. Badary OA: Taurine attenuates Fanconi syndrome induced by ifosfamide without compromising its antitumor activity. Oncol Res 1998;10:355–360.

    External Resources

  15. Jones DP, Miller LA, Chesney RW: Adaptive regulation of taurine transport in two continuous renal epithelial cell lines. Kidney Int 1990;38:219–226.
  16. Wrenn HT, Feichtmeir TV: The quantitation of albumin based on dye linear binding capacity. Am J Clin Pathol 1956;26:960–968.
  17. Bonsnes RW, Taussky HN: On the colorimetric determination of creatinine by Jaffe reaction. J Biol Chem 1945;158:581–591.
  18. Hallet GJ, Cook JG: Reduced nicotinamide adenine dinucleotide for emergency blood urea estimation. Clin Chim Acta 1971;35:33–37.
  19. Ellman GL: Tissue sulfhydryl groups. Arch Biochem Biophys 1959;82:70–77.
  20. Paglia DE, Valentine WN: Studies on the quantitative and qualitative characterization of erythrocyte glutathione peroxidase. J Lab Clin Med 1967;70:158.
  21. Ohkawa H, Ohishi N, Yagi K: Assay of lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem 1979;95:351–358.
  22. Yoshida M, Iizuka K, Terada A, Hara M, Nishijima H, Akinori, Shimata, Nakada K, Satoh Y, Akama Y: Prevention of nephrotoxicity of cisplatin by repeated oral administration of ebselen in rats. Tohoku J Exp Med 2000;191/4:209–220.
  23. Greggi Antunes LM, Darin JD, Bianchi MD: Protective effects of vitamin C against cisplatin-induced nephrotoxicity and lipid peroxidation in adult rats: A dose dependent study. Pharmacol Res 2000;41:405–411.

    External Resources

  24. Ikeda S, Fukuzaki A, Kaneto H, Ishidoya S, Orikasa S: Role of protein kinase C in cisplatin nephrotoxicity. Int J Urol 1999;6/5:245–250.
  25. Lau AH: Apoptosis induced by cisplatin nephrotoxic injury. Kidney Int 1999;56:1295–1298.

    External Resources

  26. Blochl-Daum B, Pehamberger H, Kurz C, Kyrle PA, Wagner O, Muller M, Monitzer B, Eichler HG: Effects of cisplatin on urinary thromboxane B2 excretion. Clin Pharmacol Ther 1995;58:418–424.

    External Resources

  27. Abdel-Gayoum AA, El-Jenjan KB, Ghwarsha KA: Hyperlipidaemia in cisplatin-induced nephrotic rats. Hum Exp Toxicol 1999;18:454–459.

    External Resources

  28. Saad SY, Najjar TAO, Noreddin AM, Al-Rikabi AC: Effects of gemcitabine on cisplatin-induced nephrotoxicity in rats: Schedule-dependent study. Pharmacol Res 2001;43/2:193–198.
  29. Dawson R Jr, Liu S, Eppler B, Patterson T: Effects of dietary taurine supplementation or deprivation in aged male Fischer 344 rats. Mech Ageing Dev 1999;107/1:73–91.
  30. Ideishi M, Miura S, Sakai T, Sasaguri M, Misumi Y, Arakawa K: Taurine amplifies renal kallikrein and prevents salt-induced hypertension in Dahl rats. J Hypertens 1994;12:653–661.
  31. Schaffer SW, Lombardini JB, Azuma J: Interaction between the actions of taurine and angiotensin II. Amino Acids 2000;18:305–318.

    External Resources

  32. Noulin JF, Bronchiero E, Lapointe JY, Laprade R: Two types of K(+) channels at the basolateral membrane of proximal tubule: Inhibitory effect of taurine. Am J Physiol 1999;277:F290–F297.

    External Resources

  33. Studer RK, Craven PA, DeRubertis FR: Antioxidant inhibition of protein kinase C-signaled increases in transforming growth factor-beta in mesangial cells. Metabolism 1997;48:918–925.
  34. Melino G, Catani MV, Corrazzari M, Guerrieri P, Bernassola F: Nitric oxide can inhibit apoptosis or switch it into necrosis. Cell Mol Life Sci 2000;57:612–622.
  35. Chiueh CC, Rauhala P: The redox pathway of s-nitrosoglutathione, glutathione and nitric oxide in cell to neuron communications. Free Radic Res 1999;31:641–650.
  36. Schuller-Levis G, Quinn MR, Wright C, Park E: Taurine protects against oxidant-induced lung injury: Possible mechanism(s) of action. Adv Exp Med Biol 1994;359:31–39.


Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50